Anti-TRBC1 CAR-T cell therapy (Shanghai General Hospital)

N/A

Report date: 2023/05/05 17:09:36

Base Information

Drug NameAnti-TRBC1 CAR-T cell therapy (Shanghai General Hospital)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-TRBC1
TargetsTRBC1
Therapy Area/IndicationsHematologic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator Companies +[1]  N/A
China Registration ClassN/A

Develop Information

Active Companies +[1]  N/A
Inactive CompaniesN/A
Active IndicationsHematologic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A